A Phase 4 interventional study of lidocaine and prilocaine in Periodontal Disease, sponsored by Dentsply International. Completed at 1 site in United States. Open to participants aged 6 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-07.
Sponsored by Dentsply International · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Periodontal Diseases with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Periodontal Diseases · United States.
Among the 91 studies in Periodontal Diseases with a site in United States, this one is the 58th largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2010, is one of 6 in phase 4, and was the 27th registered.
867 studies on the registry are indexed under Periodontal Diseases; 189 are open to participants now.
Browse Periodontal Diseases studies →15 of the 91 studies in Periodontal Diseases with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 21–75
Medical University of South Carolina · Sites in United States
Ages 18+ · Healthy volunteers
State University of New York at Buffalo · Sites in United States
Ages 18–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–18 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Periodontal Diseases studies recruiting now, 47 (47%) set no upper age limit and 42 (42%) stop at 75 or younger; 5 take children under 18; 58 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 7 · Phase 4 6
First in 1998; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 45 across 557 interventional studies indexed under Periodontal Diseases.
Median enrollment 60 across the 61 interventional studies, 89 across the 30 observational. Of the 66 that completed or were terminated, 18 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Dentsply International, one of the names counted as Dentsply Sirona. Under that name alone:
Dentsply International is the lead sponsor of 10 studies on the registry; none are open to participants now.
Dentsply Sirona has 1 study filed under Periodontal Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Periodontal Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07095556Medical University of South CarolinaImpact of Nd:YAG Laser Photobiostimulation on Healing of Gingiva | 2026-12 |
| NCT06948162University of MinnesotaExploration of the Utility of Dental-dedicated MRI for Dentistry | 2027-03-31 |
| NCT06149585Case Western Reserve UniversityChanges in Microbial Status From Dentate, Edentulous and After Dental Implant Placement | 2027-05-01 |
| NCT07054008The University of Texas Health Science Center at San AntonioMicrosurgery and Periodontal Healing | 2027-05-31 |
| NCT07468929Ohio State UniversitySerum Inflammatory Protein Concentration During Dental Treatment | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 91 studies in Periodontal Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To establish Oraqix is safe when used on adolescent volunteers.
This is a single-center, uncontrolled, open-label, single administration patient study. Male and female subjects aged 6 through 17 years of age in need of primary tooth extraction will be recruited from the Principal Investigator's database and may be supplemented by advertising. Subjects who withdraw from the study prematurely will be replaced.
Subjects will undergo an initial screening visit at which eligibility will be determined. After completion of informed consent/assent a physical examination, vitals, 12-lead ECG, and dental examination will be conducted. A medical history will be documented and a blood sample will be collected for analysis of biochemistry, hematology and as appropriate, serum pregnancy assessment for females.
Subjects will return to the office approximately 1 to 10 days after Visit 1 for Visit 2. At Visit 2, study treatment will be administered and PK blood samples will be collected for analysis, and monitored for safety parameters. Up to a total of five cartridges of Oraqix® will be administered to the oral cavity in the area of the tooth extraction, based on the body weight of the subject. No more than five cartridges will be dispensed, since this is the maximum dose for this agent. The final sample will be collected 4 hours after administration of study material. An abbreviated dental examination will be conducted, any adverse events (AEs) will be documented and the subject will be discharged from the clinic.
All subjects will be contacted by telephone approximately 24 hours after administration of study treatment. Study personnel will enquire about the occurrence of any AEs that have occurred since leaving the office. If appropriate, further follow-up of AEs will be arranged. In the absence of any ongoing AEs requiring follow up the subject will be considered to have completed the study at the completion of the telephone call.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: lidocaine and prilocaine
Drug pages: Lidocaine · Prilocaine
Appropriate dose of Oraqix based on weight will be given before tooth extraction
Also known as: Oraqix periodontal gel
Pharmacokinetics
The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).
Time frame: 5, 10, 15, 30, 60, 90, 120, and 240 minutes
Safety
The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose. ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals. Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose. For each subject, phone call was made at +24h as follow up pursuant to the protocol.
Time frame: blood draws pre-dose, 2 and 4 hours postdose
Vital Signs (Pulse)
Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
Time frame: Pre-dose and every 10 minute to 240 minutes post-dose.
Vital Signs (Systolic Pressure)
Time frame: Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
Vital Signs (Diastolic Pressure)
Time frame: Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose
ECGs (Ventricular Heart Rate)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
ECGs (PR Interval)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
ECGs (QRS Duration)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
ECGs (QT Interval)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
ECGs (QTcB Interval)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
| Milestone | Oraqix for Tooth Extraction |
|---|---|
| Started | 16 |
| Completed | 15 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).
| ng/mL | Lidocaine Cmax | Prilocaine Cmax | 2,6-xylidine Cmax | O-toluidine Cmax |
|---|---|---|---|---|
| Pharmacokinetics | 89.9 ± 66 | 41.8 ± 60.6 | 3.72 ± 48.5 | 5.13 ± 51.2 |
The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose. ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals. Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose. For each subject, phone call was made at +24h as follow up pursuant to the protocol.
| Percentage MetHb | % MetHemoglobin (MetHb) Time Point -20 Minutes | % MetHemoglobin (MetHb) Time Point -10 Minutes | % MetHemoglobin (MetHb) Time Point 0 Minutes | % MetHemoglobin (MetHb) Time Point 10 Minutes | % MetHemoglobin (MetHb) Time Point 20 Minutes | % MetHemoglobin (MetHb) Time Point 30 Minutes | % MetHemoglobin (MetHb) Time Point 40 Minutes | % MetHemoglobin (MetHb) Time Point 50 Minutes | % MetHemoglobin (MetHb) Time Point 60 Minutes | % MetHemoglobin (MetHb) Time Point 70 Minutes | % MetHemoglobin (MetHb) Time Point 80 Minutes | % MetHemoglobin (MetHb) Time Point 90 Minutes | % MetHemoglobin (MetHb) Time Point 100 Minutes | % MetHemoglobin (MetHb) Time Point 110 Minutes | % MetHemoglobin (MetHb) Time Point 120 Minutes | % MetHemoglobin (MetHb) Time Point 130 Minutes | % MetHemoglobin (MetHb) Time Point 140 Minutes | % MetHemoglobin (MetHb) Time Point 150 Minutes | % MetHemoglobin (MetHb) Time Point 160 Minutes | % MetHemoglobin (MetHb) Time Point 170 Minutes | % MetHemoglobin (MetHb) Time Point 180 Minutes | % MetHemoglobin (MetHb) Time Point 190 Minutes | % MetHemoglobin (MetHb) Time Point 200 Minutes | % MetHemoglobin (MetHb) Time Point 210 Minutes | % MetHemoglobin (MetHb) Time Point 220 Minutes | % MetHemoglobin (MetHb) Time Point 230 Minutes | % MetHemoglobin (MetHb) Time Point 240 Minutes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Safety | 1.3 ± 0.24 | 1.3 ± 0.26 | 1.2 ± 0.20 | 1.2 ± 0.20 | 1.3 ± 0.18 | 1.5 ± 0.43 | 1.5 ± 0.20 | 1.6 ± 0.19 | 1.7 ± 0.28 | 1.7 ± 0.30 | 1.5 ± 0.35 | 1.5 ± 0.40 | 1.5 ± 0.39 | 1.6 ± 0.19 | 1.5 ± 0.32 | 1.5 ± 0.29 | 1.4 ± 0.28 | 1.4 ± 0.26 | 1.3 ± 0.34 | 1.2 ± 0.47 | 1.4 ± 0.15 | 1.4 ± 0.17 | 1.5 ± 0.20 | 1.4 ± 0.18 | 1.4 ± 0.13 | 1.5 ± 0.14 | 1.4 ± 0.15 |
The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).
| hours | Lidocaine Tmax | Prilocaine Tmax | 2,6-xylidine Tmax | O-toluidine Tmax |
|---|---|---|---|---|
| Pharmacokinetics | 0.500 (0.0833 to 0.650) | 0.500 (0.0833 to 0.650) | 1.50 (0.650 to 4.00) | 1.50 (1.00 to 1.50) |
Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
| Beats per minute | Vital Signs (Pulse Rate), - 20 Minutes Pre-dose | Vital Signs (Pulse Rate), - 10 Minutes Pre-dose | Vital Signs (Pulse Rate), 0 Minutes Pre-dose | Vital Signs (Pulse Rate), 10 Minutes Post-dose | Vital Signs (Pulse Rate), 20 Minutes Post-dose | Vital Signs (Pulse Rate), 30 Minutes Post-dose | Vital Signs (Pulse Rate), 40 Minutes Post-dose | Vital Signs (Pulse Rate), 50 Minutes Post-dose | Vital Signs (Pulse Rate), 60 Minutes Post-dose | Vital Signs (Pulse Rate), 70 Minutes Post-dose | Vital Signs (Pulse Rate), 80 Minutes Post-dose | Vital Signs (Pulse Rate), 90 Minutes Post-dose | Vital Signs (Pulse Rate), 100 Minutes Post-dose | Vital Signs (Pulse Rate), 110 Minutes Post-dose | Vital Signs (Pulse Rate), 120 Minutes Post-dose | Vital Signs (Pulse Rate), 130 Minutes Post-dose | Vital Signs (Pulse Rate), 140 Minutes Post-dose | Vital Signs (Pulse Rate), 150 Minutes Post-dose | Vital Signs (Pulse Rate), 160 Minutes Post-dose | Vital Signs (Pulse Rate), 170 Minutes Post-dose | Vital Signs (Pulse Rate), 180 Minutes Post-dose | Vital Signs (Pulse Rate), 190 Minutes Post-dose | Vital Signs (Pulse Rate), 200 Minutes Post-dose | Vital Signs (Pulse Rate), 210 Minutes Post-dose | Vital Signs (Pulse Rate), 220 Minutes Post-dose | Vital Signs (Pulse Rate), 230 Minutes Post-dose | Vital Signs (Pulse Rate), 240 Minutes Post-dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vital Signs (Pulse) | 74 (58 to 98) | 72 (54 to 90) | 72 (60 to 95) | 79 (59 to 101) | 71 (58 to 89) | 72 (56 to 94) | 71 (55 to 86) | 70 (54 to 86) | 71 (55 to 86) | 74 (61 to 89) | 72 (57 to 86) | 71 (53 to 90) | 70 (54 to 91) | 72 (57 to 88) | 70 (52 to 86) | 71 (58 to 91) | 72 (53 to 97) | 72 (55 to 98) | 74 (58 to 93) | 74 (57 to 100) | 73 (53 to 91) | 72 (50 to 90) | 75 (62 to 90) | 72 (54 to 97) | 70 (53 to 96) | 72 (57 to 96) | 77 (62 to 101) |
| mmHg | Vital Signs (Systolic), - 20 Minutes Pre-dose | Vital Signs (Systolic), - 10 Minutes Pre-dose | Vital Signs (Systolic), 0 Minutes Pre-dose | Vital Signs (Systolic), 10 Minutes Post-dose | Vital Signs (Systolic), 20 Minutes Post-dose | Vital Signs (Systolic), 30 Minutes Post-dose | Vital Signs (Systolic), 40 Minutes Post-dose | Vital Signs (Systolic), 50 Minutes Post-dose | Vital Signs (Systolic), 60 Minutes Post-dose | Vital Signs (Systolic), 70 Minutes Post-dose | Vital Signs (Systolic) 80 Minutes Post-dose | Vital Signs (Systolic), 90 Minutes Post-dose | Vital Signs (Systolic), 100 Minutes Post-dose | Vital Signs (Systolic), 110 Minutes Post-dose | Vital Signs (Systolic), 120 Minutes Post-dose | Vital Signs (Systolic), 130 Minutes Post-dose | Vital Signs (Systolic), 140 Minutes Post-dose | Vital Signs (Systolic), 150 Minutes Post-dose | Vital Signs (Systolic), 160 Minutes Post-dose | Vital Signs (Systolic), 170 Minutes Post-dose | Vital Signs (Systolic), 180 Minutes Post-dose | Vital Signs (Systolic), 190 Minutes Post-dose | Vital Signs (Systolic), 200 Minutes Post-dose | Vital Signs (Systolic), 210 Minutes Post-dose | Vital Signs (Systolic), 220 Minutes Post-dose | Vital Signs (Systolic), 230 Minutes Post-dose | Vital Signs (Systolic), 240 Minutes Post-dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vital Signs (Systolic Pressure) | 110 ± 11.5 | 104 ± 9.4 | 106 ± 9.1 | 115 ± 9.7 | 109 ± 7.9 | 108 ± 9.4 | 106 ± 9.8 | 106 ± 9.6 | 105 ± 12.1 | 106 ± 7.9 | 104 ± 11.0 | 106 ± 9.7 | 106 ± 9.9 | 106 ± 10.7 | 106 ± 11.4 | 105 ± 8.9 | 108 ± 8.0 | 107 ± 8.4 | 105 ± 10.7 | 106 ± 9.6 | 104 ± 10.2 | 103 ± 10.7 | 103 ± 10.9 | 102 ± 9.2 | 104 ± 10.8 | 102 ± 10.6 | 102 ± 11.7 |
| mmHg | Vital Signs (Diastolic), - 20 Minutes Pre-dose | Vital Signs (Diastolic), - 10 Minutes Pre-dose | Vital Signs (Diastolic), 0 Minutes Pre-dose | Vital Signs (Diastolic), 10 Minutes Post-dose | Vital Signs (Diastolic), 20 Minutes Post-dose | Vital Signs (Diastolic), 30 Minutes Post-dose | Vital Signs (Diastolic), 40 Minutes Post-dose | Vital Signs (Diastolic), 50 Minutes Post-dose | Vital Signs Diastolic(), 60 Minutes Post-dose | Vital Signs (Diastolic), 70 Minutes Post-dose | Vital Signs (Diastolic) 80 Minutes Post-dose | Vital Signs (Diastolic), 90 Minutes Post-dose | Vital Signs (Diastolic), 100 Minutes Post-dose | Vital Signs (Diastolic), 110 Minutes Post-dose | Vital Signs (Diastolic), 120 Minutes Post-dose | Vital Signs Diastolic(), 130 Minutes Post-dose | Vital Signs (Diastolic), 140 Minutes Post-dose | Vital Signs (Diastolic), 150 Minutes Post-dose | Vital Signs (Diastolic), 160 Minutes Post-dose | Vital Signs (Diastolic), 170 Minutes Post-dose | Vital Signs (Diastolic), 180 Minutes Post-dose | Vital Signs (Diastolic), 190 Minutes Post-dose | Vital Signs (Diastolic), 200 Minutes Post-dose | Vital Signs (Diastolic), 210 Minutes Post-dose | Vital Signs (Diastolic), 220 Minutes Post-dose | Vital Signs (Diastolic), 230 Minutes Post-dose | Vital Signs (Diastolic), 240 Minutes Post-dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vital Signs (Diastolic Pressure) | 63 ± 6.8 | 60 ± 7.2 | 63 ± 7.2 | 69 ± 7.9 | 63 ± 6.2 | 64 ± 5.6 | 62 ± 8.7 | 62 ± 11.2 | 62 ± 7.7 | 62 ± 10.8 | 62 ± 9.3 | 64 ± 7.6 | 63 ± 7.6 | 63 ± 11.4 | 60 ± 7.6 | 62 ± 7.9 | 62 ± 7.2 | 63 ± 9.1 | 63 ± 6.6 | 60 ± 6.8 | 60 ± 8.8 | 61 ± 7.1 | 60 ± 7.6 | 59 ± 7.5 | 57 ± 6.9 | 57 ± 6.9 | 60 ± 8.4 |
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
| Beats per minute | Ventricular Heart Rate, Pre-dose | Ventricular Heart Rate, 1 Hour Post-dose | Ventricular Heart Rate, 2 Hour Post-dose | Ventricular Heart Rate, 4 Hour Post-dose |
|---|---|---|---|---|
| ECGs (Ventricular Heart Rate) | 73 ± 9.9 | 70 ± 8.3 | 71 ± 6.5 | 74 ± 10.1 |
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
| milliseconds | PR Interval, Pre-dose | PR Interval, 1 Hour Post-dose | PR Interval, 2 Hour Post-dose | PR Interval, 4 Hour Post-dose |
|---|---|---|---|---|
| ECGs (PR Interval) | 148 ± 21.1 | 147 ± 23.7 | 147 ± 22.4 | 139 ± 18.9 |
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
| milliseconds | QRS Duration, Pre-dose | QRS Duration, 1 Hour Post-dose | QRS Duration, 2 Hour Post-dose | QRS Duration, 4 Hour Post-dose |
|---|---|---|---|---|
| ECGs (QRS Duration) | 77 ± 5.7 | 76 ± 4.5 | 75 ± 7.5 | 74 ± 5.3 |
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
| milliseconds | QT Interval, Pre-dose | QT Interval, 1 Hour Post-dose | QT Interval, 2 Hour Post-dose | QT Interval, 4 Hour Post-dose |
|---|---|---|---|---|
| ECGs (QT Interval) | 376 ± 22.5 | 384 ± 19.3 | 383 ± 19.0 | 379 ± 25.8 |
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
| milliseconds | QTcB Interval, Pre-dose | QTcB Interval, 1 Hour Post-dose | QTcB Interval, 2 Hour Post-dose | QTcB Interval, 4 Hour Post-dose |
|---|---|---|---|---|
| ECGs (QTcB Interval) | 412 ± 19.0 | 413 ± 21.9 | 415 ± 18.6 | 419 ± 21.1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adverse Events | — | 0/16 (0%) | 2/16 (12.5%) |
| Event | Adverse Events |
|---|---|
| NauseaGastrointestinal disorders | 2/16 |
| GaggingGastrointestinal disorders | 1/16 |
| VomitingGastrointestinal disorders | 1/16 |
| Tooth painNervous system disorders | 1/16 |
| HeadacheNervous system disorders | 1/16 |
| Age, Categorical(Participants) | Oraqix for Tooth Extraction |
|---|---|
| <=18 years | 16 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Oraqix for Tooth Extraction |
|---|---|
| Female | 9 |
| Male | 7 |
| Region of Enrollment(participants) | Oraqix for Tooth Extraction |
|---|---|
| United States | 16 |
The record gives a start of Apr 2010, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lidocaine · Prilocaine